I was thrilled to be joined by Prof Marco Proietti to discuss important #VTE and #AFib trials presented at the ESC meeting. Lots of great science that impacts how we care for patients with #cvCoag meds. www.medthority.com/medical-educ... @medthority.bsky.social

Help us understand what stewardship practices exist in health systems globally for #cvCoag and antithrombotic agents in the properties space! redcap.slhd.nsw.gov.au/surveys/?s=7... #ISTH2025 @isth.org @anticoagforum.bsky.social

I often get asked if it’s safe to use #cvCoag mono therapy in patients with AF and stable CAD (i.e., PCI>6-12 months prior). @bbikdeli.bsky.social clearly shows safety and efficacy with OAC motherly in this population. #ACForum25

Andrea Van Beek reminds us of ways the traditional “Coumadin Clinic” can evolve to have greater impact in helping our patients achieve evidence-based #cvCoag therapy. #ACForum25

Congratulations to Drs Anne Rose, Tara Lech, David Para, and Allison Burnett for their leadership in Antithrombotic Stewardship. Each of them is a pioneer in patient safety in #cvCoag care. #ACForum25 @anticoagpharmd.bsky.social

This brand new analysis of the OCEANIC-AF study in @jama.com Cardiology explores the impact of prior #cvCoag treatment for #AF on using Factor XIa inhibitors. Does this challenge the belief that bleeding is front-loaded while stroke-risk is continuous in AF tx? jamanetwork.com/journals/jam...

What is the most effective way for large #cvCoag clinics to manage warfarin-treated patients? We found that moving to a "primary staff care" model where patients are assigned to individual staff/teams was the most effective. Read more here: www.sciencedirect.com/science/arti...

When does @bbikdeli.bsky.social sleep? I'm not sure - he's constantly publishing highly impactful work!! This week is no different. Check out this important meta-analysis on #cvCoag and #antiplatleet use in #AFib and stable #CAD! Less is more!!! @jaccjournals.bsky.social www.jacc.org/doi/10.1016/...

Can a decision aid improve #AFib patient #cvCoag decision-making? Our 1117-patient randomized trial in the BMJ, showed improved decisional conflict, better shared decision-making, and greater patient knowledge. Check it out here: www.bmj.com/content/388/... www.bmj.com/content/bmj/...

DOACs have been "the thing" in #cvCoag for over 10 years. What's coming next? Check out this brand new review article on emerging anti-thrombotic agents, focused on factor XI and GPVI agents, just published in @jthjournal.bsky.social! www.sciencedirect.com/science/arti...

Apixaban rarely raises INR to clinically significant levels. An analysis by DCRI fellow Seamus Hughes showed that, among 8,642 ARISTOTLE patients, the median INR was just 1.18. Elevated INR on a DOAC? Consider non-drug causes. #ACC26 #AFib #cvCoag #CardioSky

A 🆕 ACC Scientific Statement published in #JACC provides evidence-based guidance on the use of DOACs in primary and secondary prevention of thrombotic events.

Get full details ➡️ https://bit.ly/4bkpwdI #cvCoag #cvVTE #CardioSky #MedSky

#ACC26: 🆕 Insights from the CHAMPION-AF trial

Device-based LAA closure was comparable to NOAC therapy in reducing the combined rate of death from CV causes, stroke, or systemic embolism at 3️⃣ years in pts w/ #AFib who were candidates for #cvCoag.

More: https://bit.ly/4bIv5SA #CardioSky #MedSky

🔥 #ACC26: HI-PEITHO

In patients with acute, intermediate-risk PE, ultrasound-facilitated, catheter-directed fibrinolysis plus #cvCoag led to a lower risk of PE-related death, cardiopulmonary decompensation or collapse, or recurrence of PE compared w/ anticoagulation alone. 🔗 https://bit.ly/4cbcwIf

Dr. Isabelle Mahe on the extended anticoagulant treatment with a reduced versus full dose #apixaban in patients with cancer-associated #VTE

#ACC25 #JACCJournals #APICAT #CardioOnc #cvCoag #CardioSky